biotech
Merck Licenses Coley Pharma's VaxImmune for $4 Million
Filed in archive Corporate and Industrial News by ruth on April 13, 2007
Merck Licenses Coley Pharma's VaxImmune for $4 Million
Merck & Co., Inc. has licensed Coley Pharmaceutical's VaxImmune(TM) vaccine adjuvant for an upfront license fee of $4 million, and milestone fess of up to $33 million plus royalties.
VaxImmune is a proprietary Toll-like receptor 9 (TLR9) agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.

VaxImmune is currently under clinical trials for various cancer, infectious disease and biowarfare applications.

Source: Coley Pharmaceutical
Photo: TLR Therapeutics, Coley Pharmaceuticals

Permalink: Merck Licenses Coley Pharma's VaxImmune for $4 Million
Tags: merck  license  investment  pharma  vaximmune  vaccine  biotech  coley  vaximmune+million 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/63383
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Merck Licenses Coley Pharma's VaxImmune for $4 Million:

  • Currently 9.67/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.67 out of 3 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!